Regulatory and Clinical

The company shared results from the clinical study.

Regulatory exclusivity extends until May 3, 2032.

The clearance allows the company to market its innovative medical device.

Trial met primary endpoint for Phentolamine Ophthalmic Solution 0.75%.

Statistically significant results achieved for primary and key secondary endpoints.

First patient dosed in the trial of the novel lithium-delivery system.